ArticleMolecular diversity2024
In-vitro antiviral activity and in-silico targeted study of quinoline-3-carboxylate derivatives against SARS-Cov-2 isolate.
Article in Molecular diversity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Recent Advances in Nitrogen-Containing Heterocyclic Scaffolds as Antiviral Agents.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2024Pooled it
- Insects on the Plate: Nutritional Benefits, Health Impacts, and Market Dynamics.Current protein & peptide science · 2026Review
- The Role of Coumarins in Drug Discovery: Pharmacological Insights and Structural Innovations.Current topics in medicinal chemistry · 2026Review
- Spirulina Unveiled: A Comprehensive Review on Biotechnological Innovations, Nutritional Proficiency, and Clinical Implications.Current pharmaceutical biotechnology · 2025Review
- Superfoods in Drug Discovery: Nutrient Profiles and their Emerging Health Benefits.Current drug discovery technologies · 2025Review
- From Bugs to Benefits: Edible Insects as Exceptional Protein Sources.Current protein & peptide science · 2025Review
- Biotechnological Breakthroughs in Resveratrol Synthesis and Health Advancements.Current pharmaceutical biotechnology · 2025Review
- Exploring Edible Insects: A Review on Protein Diversity, Extraction Techniques and Health Benefits.Current pharmaceutical biotechnology · 2025Review
- Nitrogen-fused Heterocycles: Empowering Anticancer Drug Discovery.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In recent years, the viral outbreak named COVID-19 showed that infectious diseases have a huge impact on both global health and the financial and economic sectors. The lack of efficacious antiviral drugs worsened the health problem. Based on our previous experience, we investigated in vitro and in silico a series of quinoline-3-carboxylate derivatives against a SARS-CoV-2 isolate. In the present study, the in-vitro antiviral activity of a series of quinoline-3-carboxylate compounds and the in silico target-based molecular dynamics (MD) and metabolic studies are reported. The compounds' activity against SARS-CoV-2 was evaluated using plaque assay and RT-qPCR. Moreover, from the docking scores, it appears that the most active compounds (1j and 1o) exhibit stronger binding affinity to the primary viral protease (NSP5) and the exoribonuclease domain of non structural protein 14 (NSP14). Additionally, the in-silico metabolic analysis of 1j and 1o defines CYP2C9 and CYP3A4 as the major P450 enzymes involved in their metabolism.
Indexed as
Identifiers
37480422What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.